Literature DB >> 17697524

Use of (99m)Tc-sulesomab for the diagnosis of prosthesis infection after total joint arthroplasty.

E E Pakos1, A D Fotopoulos, K S Stafilas, I Gavriilidis, G Al Boukarali, S Tsiouris, T A Xenakis.   

Abstract

This study aimed to evaluate the diagnostic efficacy of antigranulocyte scintigraphy using the antibody fragment (99m)Tc-sulesomab (LeukoScan) for the diagnosis of prosthesis infection in patients with total hip or knee arthroplasty. The results from 19 patients with suspected total joint arthroplasty infection who had undergone a three-phase bone scan and a subsequent examination with (99m)Tc-sulesomab during a 1-year period were reviewed. Twelve patients were shown to have prosthesis infection on culture of aspirated synovial fluid or intra-operative samples. The overall sensitivity, specificity, positive and negative predictive values, and diagnostic accuracy for (99m)Tc-sulesomab were 75%, 86%, 90%, 66% and 79%, respectively, compared with 54%, 83%, 88%, 45% and 63%, respectively, for the three-phase bone scan. This study showed that (99m)Tc-sulesomab had good diagnostic value for the detection of prosthesis infection. The combination of (99m)Tc-sulesomab with other laboratory or imaging examinations may improve diagnostic performance in prosthesis infection and should be investigated further.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17697524     DOI: 10.1177/147323000703500406

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  2 in total

Review 1.  Nuclear medicine and the failed joint replacement: Past, present, and future.

Authors:  Christopher J Palestro
Journal:  World J Radiol       Date:  2014-07-28

2.  Use of anti-granulocyte scintigraphy with 99mTc-labeled monoclonal antibodies for the diagnosis of periprosthetic infection in patients after total joint arthroplasty: a diagnostic meta-analysis.

Authors:  Dan Xing; Xinlong Ma; Jianxiong Ma; Jie Wang; Yang Chen; Yang Yang
Journal:  PLoS One       Date:  2013-07-26       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.